View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 23, 2022

Cue Biopharma doses first subject in Phase I trial of WT1-expressing cancers

The trial will analyse the safety, tolerability, anti-tumour activity, and immunogenicity of CUE-102.

Cue Biopharma has dosed the first subject in a Phase I dose escalation clinical trial of its drug candidate, CUE-102, as a single agent to treat Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancer patients. 

In the initial stage, the trial will focus on gastric, colorectal, ovarian, and pancreatic cancers.

The open-label, multicentre, dose escalation and expansion trial will analyse the safety, tolerability, anti-tumour activity, and immunogenicity of CUE-102.

It will enrol nearly 50 HLA-A*0201-positive WT1-positive recurrent/metastatic cancer patients who have failed standard treatments. 

The second candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics, CUE-102, is in the development stage as a new therapeutic fusion protein. 

It is said to selectively trigger tumour antigen-specific T cells for treating WT1-expressing cancers. 

CUE-102 comprises two WT1 peptide-presenting human leukocyte antigen (HLA) molecules, four affinity-attenuated IL-2 molecules, and an effector attenuated human immunoglobulin G (IgG1) Fc domain. 

Cue Biopharma CEO Dan Passeri said: “Initiating this Phase I clinical study of CUE-102 at a starting dose of 1mg/kg, a clinically active dose in our Phase I CUE-101 clinical trial for HPV+ head and neck cancer, is an important step forward in demonstrating the modularity of our Immuno-STAT platform and the broader clinical potential of our CUE-100 series of biologics. 

“We believe, given the preservation of the core molecular framework between CUE-102 and CUE-101 with the primary exception of the tumour-specific epitope, initiating the dose escalation trial at 1mg/kg will result in reduced time and cost to evaluate tolerability at therapeutically active doses.”

WT1 is a known onco-foetal protein over-expressed in various cancers including hematologic malignancies and solid tumours such as glioblastoma, gastric, pancreatic, endometrial, breast, lung, ovarian, colorectal, and acute myeloid leukaemia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena